类有机物
体内
结直肠癌
头颈部鳞状细胞癌
癌症研究
放射治疗
医学
细胞培养
腺癌
体外
药品
病理
生物
头颈部癌
癌症
内科学
药理学
细胞生物学
生物技术
生物化学
遗传学
作者
Marrit Putker,Rosemary Millen,René M. Overmeer,Else Driehuis,Maurice M.J.M. Zandvliet,Hans Clevers,Sylvia F. Boj,Qi‐Xiang Li
摘要
Patient-derived organoid (PDO) models allow for long-term expansion and maintenance of primary epithelial cells grown in three dimensions and a near-native state. When derived from resected or biopsied tumor tissue, organoids closely recapitulate in vivo tumor morphology and can be used to study therapy response in vitro. Biobanks of tumor organoids reflect the vast variety of clinical tumors and patients and therefore hold great promise for preclinical and clinical applications. This paper presents a method for medium-throughput drug screening using head and neck squamous cell carcinoma and colorectal adenocarcinoma organoids. This approach can easily be adopted for use with any tissue-derived organoid model, both normal and diseased. Methods are described for in vitro exposure of organoids to chemo- and radiotherapy (either as single-treatment modality or in combination). Cell survival after 5 days of drug exposure is assessed by measuring adenosine triphosphate (ATP) levels. Drug sensitivity is measured by the half-maximal inhibitory concentration (IC50), area under the curve (AUC), and growth rate (GR) metrics. These parameters can provide insight into whether an organoid culture is deemed sensitive or resistant to a particular treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI